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Abstract 
Objective  To assess antihypertensive management of older patients with poor blood pressure (BP) control. Methods  Physicians, volun-
tary participating in the study, included six consecutive hypertensive patients during routine visits. Hypertension had to have been previously rec-
ognized and averaged office BP was ≥ 140 and/or ≥ 90 mmHg in spite of ≥ 6 weeks of antihypertensive therapy. The physicians completed a 
questionnaire on patients’ history of cardiovascular (CV) risk factors, comorbidities, home BP monitoring, anthropometric data and the pharma-
cotherapy. Results  Mean age of the 6462 patients was 61 years, 7% were ≥ 80 years, 51% were female. Mean ± SD office BP values were 158 
± 13/92 ± 10 mmHg. The most commonly prescribed antihypertensive drugs were: diuretics (67%), ACE inhibitors (64%), calcium channel 
blockers (58%) and β-blockers (54%), and their use increased with age. On monotherapy or dual therapy, 43% of the patients and 40% had their 
latest treatment modification within six months. Home BP monitoring was a factor that accelerated the modification of the therapy. Older patients 
had to have less chance on faster modification of antihypertensive therapy in spite of presence of diabetes and higher systolic BP. Conclusions  
Our study suggests that a large number of outpatients with poor BP control receive suboptimal antihypertensive therapy, especially in primary care. 
In older patients, higher BP values in the office settings are more frequently accepted by physicians even in case of higher CV risk. Regular home 
BP monitoring hastens the decision to intensify of antihypertensive treatment. 
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1  Introduction 
In spite of increased in public awareness, hypertension 
remains one of the most important health problems, as a risk 
factor of cardiovascular (CV) and cerebrovascular morbid-
ity and mortality, dementia, renal failure and blindness.[1] 
Moreover, the prevalence of hypertension continues to in-
crease worldwide due to the aging population and unhealthy 
lifestyle behaviours.[2] Additionally, despite knowledge of 
the value of therapeutic lifestyle modifications and newer 
and newer classes of medications, the number of people 
with uncontrolled blood pressure (BP) keeps on rising.[2] 
In population-based studies, a beneficial trend toward an 
increase in awareness and control of hypertension in many 
countries has been observed.[3,4] However, while about 50% 
of treated patients remain well treated in North America, 
control rates in Europe are lower, especially in older pa-
                                                        
Correspondence to: Barbara Wizner, RN, PhD, Jagiellonian University Me-
dical College, Department of Internal Medicine and Gerontology, 10 Sniadeckich 
Str., 31-531 Cracow, Poland. E-mail: barbara.wizner@cm-uj.krakow.pl 
Telephone: +48-12-4248813 Fax: +48-12-4248854 
Received: August 20, 2018 Revised: December 24, 2018 
Accepted: January 3, 2019 Published online: January 28, 2019 
tients.[3] Data from the National Health and Nutrition Ex-
amination Survey (NHANES) revealed that among all pa-
tients on one to two antihypertensive medications, the risk 
of being uncontrolled increased by 28% with each 10-year 
increase in age.[5] In older patients, the lower rate of ade-
quate BP control may be only partly explained by an in-
creased risk of resistant hypertension (RHT).[6] 
Most hypertensive patients are managed in primary care 
settings. However, many patients are underdiagnosed and 
undertreated.[7] The reasons are complex and include a 
combination of factors related to insufficient prescribing of 
antihypertensive drugs by physicians, who want to mini-
mize the side effects of drugs by reducing their daily dose, 
unsatisfactory patient adherence to therapy and also organ-
izational factors.[8,9] 
In the recent years in Poland, a significant improvement 
in BP control has been observed among the older population 
and number of controlled hypertension doubled since 2001 
year.[4] However, about 75% of older patients still have un-
controlled BP. A better understanding of current practice in 
outpatient care might help to develop appropriate strategies 
for improving antihypertensive treatment. We therefore set 
out to assess the clinical data of patients with uncontrolled 
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BP in ambulatory care to recognize the potentially modifi-
able factors associated with poor BP control, especially in 
older patients.  
2  Methods 
2.1  Study design and population 
The nationwide non-interventional observational survey 
was conducted in Poland (May-September 2014). Each of 
the physicians (family physicians, internists, cardiologists, 
hypertension specialists) involved in the study (n = 1129) 
enrolled six consecutive patients with uncontrolled BP who 
visited their office as part of a routine control visit. The in-
clusion criteria were: age ≥ 18 years; diagnosis of hyperten-
sion had to be confirmed and documented in the patient's 
medical record; antihypertensive pharmacotherapy had been 
provided for at least six weeks; and office systolic and dia-
stolic BP during the last visit was ≥ 140 and/or ≥ 90 mmHg.  
Of 6602 eligible patients, 6462 were finally included in 
the study because of missing data on age and gender. 
2.2  BP measurement 
All physicians involved in the study were familiarized 
with the guidelines regards to proper technique of office BP 
measurement.[10,11] BP was measured during the visit in a 
sitting position after a few minutes of rest using the appro-
priate cuff sizes and validated devices. It was measured at 
least twice, with an interval 1 to 2 min between measure-
ments, and the last two BP readings were averaged and re-
corded in the study questionnaire. Pulse pressure (PP) was 
calculated as the difference between the average systolic 
and diastolic BP. 
2.3  Hypertension management 
The physicians were asked to provide detailed informa-
tion about the actual pharmacologic treatment of hyperten-
sion, including trade names of different classes of drugs. 
The physicians were also asked about changes in antihyper-
tensive therapy has been introduced during the index visit. 
Additionally, in the study questionnaire, the date of hyper-
tension diagnosis, duration of antihypertensive therapy, and 
the time since the last modification of treatment were de-
scribed. Modification of antihypertensive therapy both be-
fore and during the index visit was defined as any changes 
related either the dose or the class of drug.  
The patient was asked about regular self-measurement of 
BP at home and the last available home BP reading was noted. 
2.4  Other data collected 
Anthropometric measurements, such as weight, height 
and waist circumference, were obtained to assess body fat 
(body mass index (BMI)) and its distribution. Visceral obe-
sity was defined as waist circumference ≥ 102 cm in men 
and ≥ 88 cm in women.  
Based on medical records and an interview with the pa-
tient, the presence of traditional CV risk factors—such as 
hypercholesterolemia, family history of premature CV dis-
eases, obesity, hyperglycemia presence of comorbidities and 
target organ damage was gathered.  
2.5  Ethical issues 
Each patient included in the study was identified by the 
patient number and the patient initials (first letters of the 
patient’s name and surname). 
Prior to enrolment, the physician informed the patient 
about the study objectives and methods, as well as the scope 
of data that were disclosed for the purpose of the observa-
tional program, and the physician was obliged to obtain the 
patient’s written consent for disclosure of medical data. 
Data were collected and processed maintaining confidenti-
ality and anonymity of the surveyed patients. 
Study was conducted in accordance with art. 37al. of 
Polish Pharmaceutical Law. 
2.6  Statistical methods 
General characteristics of the surveyed patients were 
summarized in three age groups: up to 64 years, 65–79 
years, and 80 years and more. Continuous variables were 
presented as mean ± SD or median and interquartile range 
[upper-lower quartile] depending on data distribution. The 
comparative analyses between the independent groups were 
based on parametric one-way ANOVA or using GLM mod-
els with Tukey’s post hoc statistics. The Cochran-Armitage 
test was used to analyse age-related trends. The chi-square 
test was used to compare distribution of qualitative variables 
between the age groups; in cases where the numbers in 
sub-samples were small, the exact Fisher’s test was applied. 
The degree of relationship between classifications was as-
sessed by the contingency coefficient.  
Standard logistic regression analyses were performed to 
identify the factors, not related to pharmacotherapy, poten-
tially affecting the decision on implementing changes in 
antihypertensive therapy within the latest six months from 
the study visit. In unadjusted and age-sex-systolic BP ad-
justed models, we assessed the effect of gender, age, office 
systolic, diastolic BP as well as pulse pressure, patients' 
declaration on regularly performed home BP measurements, 
smoking status, abdominal obesity and presence of co-mor-
bidities such as coronary heart disease, heart failure, stroke, 
chronic kidney disease. To assess the predictors of modifi-
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cation of therapy during the index visit, we used the same 
variables. Additionally, we also included to the stepwise 
logistic regression model the variable reflecting the period 
of last modification in therapy. 
The Hosmer and Lemeshow Goodness-of-Fit test was 
applied in regression analyses to control colinearity. Two- 
sided tests were used and the P-value was set at < 0.05. Data 
were collected in Microsoft Access and analyzed using SAS 
9.3 (SAS Institute Inc., Cary, NC, USA). 
3  Results 
3.1  Baseline characteristic of the studied patients  
Mean age of the patients with poor control of BP was 
61.4 ± 11.6 years (range: 18 to 95 years), 2134 (33.0%) 
were 65 to 79 years old and 433 (6.7%) were aged 80 years 
and older. Women accounted for 50.9% (n = 3287) of the 
subjects, and their proportion steadily increased with ad-
vanced age (Table 1). Both office and home systolic BPs 
were significantly higher in older subjects in contrast to 
diastolic BPs. Consequently, an increase of pulse pressure 
(PP) with age was observed. Higher pulse pressure (≥ 60 
mmHg), a marker of arterial stiffness, was observed in over 
85% of patients > 65 years (Table 1). 
Older patients more frequently declared regular self-mea-
surement of BP at home than younger ones (< 65 years).  
3.2  CV risk factors and clinical profile  
The prevalence of traditional risk factors, such as active 
smoking or obesity, decreased with age as well as family 
history of premature CV diseases (Table 2), whereas lipid 
disorders and impaired fasting glycaemia were more com-
mon in older subjects than in patients under the age of 65 
years. The most common comorbidities in patients with 
uncontrolled BP were coronary artery disease (CAD), dia-
betes and heart failure (HF)—33.5%, 25.9% and 12.9%, 
respectively. The frequency of CAD, HF, diabetes, and 
other comorbidities such as stroke or transient ischaemic 
attack (TIA), peripheral artery disease (PAD) and chronic 
kidney disease (CKD) significantly increased with advanced 
age (Table 2). 
3.3  Pharmacotherapy 
In the studied patients, the most commonly prescribed 
antihypertensive agents were: diuretics (67%), ACE inhibi-
tors (64%), calcium channel blockers (58%), β-blockers 
(54%), and angiotensin II receptor blockers (ARBs, 22%). 
The characteristics of antihypertensive therapy according to 
age is shown in Figure 1. Except for ARBs, usage of all 
antihypertensive classes of drugs increased with advancing 
age, and diuretic with ACE inhibitor was the preferred 
combination in each age category. Some differences were 
observed in the usage of other agents; in the youngest pa-
tients, calcium channel blockers were used more commonly, 
while β-blockers were used slightly more frequently in older 
subjects (≥ 65 years).  
Overall, among the patients with poor BP control, 14% 
(n = 933) were on monotherapy, 28% (n = 1828) were on  
Table 1.  Baseline characteristics of Polish outpatients with poor blood pressure control. 
 N ≤ 64 yrs (n = 3895) 65–79 yrs (n = 2134) ≥ 80 yrs (n = 433) Ρ-value 
Age, yrs 6462 53.9 ± 7.8 70.6 ± 3.9 83.0 ± 3.2 < 0.001* 
Female 6462 1850 (47.5%) 1162 (54.4%) 275 (63.5%) < 0.001* 
BMI, kg/m2 6430 29.3 ± 4.7 29.9 ± 4.7 28.6 ± 5.0 < 0.001 
Office measurements      
Systolic BP, mmHg 6462 157.1 ± 12.6 159.1 ± 13.8 161.1 ± 15.6 < 0.001* 
Diastolic BP, mmHg 6462 92.6 ± 9.2  90.4 ± 10.7  87.5 ± 12.1 < 0.001* 
Pulse pressure, mmHg 6462  64.6 ± 12.6  68.7 ± 14.5  73.7 ± 16.0 < 0.001* 
Pulse pressure ≥ 60 mmHg 6462 2834 (72.8%) 1702 (89.8%) 376 (86.8%) < 0.001╪ 
BP ≥ 150/90 mmHg  NA NA 386 (89.2%)  
Heart rate, beats/min 6362 76.9 ± 9.3 75.4 ± 9.8 75.2 ± 10.5 < 0.001# 
Home BP      
Regular measurement 6439 2269 (58.4%) 1367 (64.4%) 256 (59.3%) 0.003 
Available data 3882 2262 (58.1%) 1364 (63.9%) 256 (59.1%) - 
Systolic BP, mmHg 3882 148.3 ± 14.1 150.0 ± 14.7 151.8 ± 19.2 < 0.001# 
Diastolic BP, mmHg 3882 88.4 ± 9.3  86.8 ± 10.3  84.2 ± 11.9 < 0.001* 
BP < 135/85 mmHg 3882 217 (9.6%) 128 (9.4%) 40 (15.6%) 0.056╪ 
Data are presented as means ± SD or n (%). *P < 0.05 for the all post-hoc comparisons between the age-categories; #P < 0.05 for the post-hoc comparison only 
with the youngest subjects (≤ 64 yrs); ╪P-value for trend (Cochran-Armitage trend test). BMI: body mass index; BP: blood pressure; NA: not applicable crite-
rion of hypertension control in population < 80 years old. 
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Table 2.  Age-related prevalence of cardiovascular risk factors and co-morbidities in hypertensive patients. 
Cardiovascular risk factors N ≤ 64 yrs (n = 3895) 65–79 yrs (n = 2134) ≥ 80 yrs (n = 433) Ρ-value 
Current smoking 1407 1058 (27.2%) 330 (15.5%) 19 (4.4%) < 0.001 
Lipid disorders 6462 2828 (72.6%) 1759 (82.4%) 322 (74.4%) < 0.001 
Impaired fasting glycaemia 6462 1116 (28.7%) 894 (41.9%) 200 (46.2%) < 0.001╪ 
Obesity 6462 1744 (44.8%) 1078 (50.5%) 158 (36.5%) < 0.001 
Abdominal obesity 6462 1972 (50.6%) 1240 (58.1%) 207 (47.8%) < 0.001 
Family history of premature CVD 6462 1672 (42.9%) 810 (38.0%) 114 (26.3%) < 0.001╪ 
Co-morbidities      
Coronary artery disease 6401 864 (22.4%) 1047 (49.5%) 251 (58.8%) < 0.001╪ 
Heart failure 6390 228 (5.9%) 432 (20.5%) 171 (40.5%) < 0.001╪ 
Diabetes 6408 766 (19.8%) 734 (34.7%) 175 (40.7%) < 0.001╪ 
Stroke or TIA 6410 169 (4.4%) 270 (12.8%) 96 (22.3%) < 0.001╪ 
Peripheral artery disease 6405 356 (9.2%) 364 (17.2%) 101 (23.6%) < 0.001╪ 
Chronic kidney disease 5728 118 (3.1%) 227 (10.8%) 107 (25.2%) < 0.001╪ 
Data are presented as n (%). Abdominal obesity was defined as waist circumference in men: 102 cm and in women: 88 cm; impaired fasting glycaemia was 
defined as 5.6 to 6.9 mmol/L or 102 to 125 mg/dL; obesity was defined if BMI ≥ 30 kg/m2; family history for premature CVD: in men < 55 and women < 65 
years old; chronic kidney disease (GFR: 3060 mL/min per 1.73 m2). ╪P-value < 0.05 for trend (Cochran-Armitage trend test). CVD: cardiovascular disease; 
GFR: glomerular filtration rate; TIA: transient ischemic attack. 
 
 
Figure 1.  Antihypertensive therapy among outpatients ac-
cording to age. (A): drug classes applied according to age; (B): 
monotherapy and combination therapy in three age groups. ACEI: 
angiotensin converting enzyme inhibitors; ARB: angiotensin II 
receptor blocker; CCB: calcium channel blocker; other: alfa- 
blocker or centrally acting. ╪P < 0.05 for trend (Cochrane-Armitage 
trend test). 
two antihypertensive drug classes and 57% (n = 3700) on 3 
or more drug classes, and in the vast majority of these pa-
tients (90%) a diuretic was included. Percentage of the sub-
jects on suboptimal therapy (mono- or dual therapy) de-
creasing with advanced age (Figure 1B). Fixed-dose com-
binations were used in 23% of the patients, most often in the 
youngest group.  
According to the inclusion criteria, all patients were on 
antihypertensive therapy for at least six weeks, but most of 
them had been treated long-term from one to five years 
(33%, n = 2149) or more than 10 years (30%, n = 1930); after-
wards, the subjects used antihypertensive treatment from 6 
to 10 years (25%, n = 1451). The smallest group consisted 
of patients on antihypertensive therapy for less than 1 year 
(11%, n = 706). 
3.4  Determinants of pharmacotherapy modification  
Approximately 10% of the patients with uncontrolled 
hypertension had their latest treatment modification within 
one month before the study visit (n = 619), 1811 (28.0%) 
between one to six months, 1261 (19.5%) between 7 and 12 
months, and 1824 (28.2%) patients more than one year be-
fore the visit. Moreover, in 769 (11.9%) patients, informa-
tion on the time of last treatment modification was not pos-
sible to determine while in 178 (2.8%) it was missing. 
Characteristic of the subjects in relation to the period of last 
changes in therapy was presented in Supplemental material 
(Table S1). In the multivariate regression analysis older age 
of the patients with poor BP control, higher systolic BP and 
presence of diabetes were significantly associated with lack 
of antihypertensive modification within six months (Table 3). 
On the contrary, regular BP measurement at home signifi-
cantly increased the chance for earlier modification of anti-
hypertensive therapy. 
Based on the physicians’ declaration we also determined 
number of patients in whom the current antihypertensive 
therapy was changed during the index visit (Table 4). Sum- 
Siga O, et al. Age-related hypertension management 23 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
Table 3.  Factors associated with lack of antihypertensive therapy modification during last six months in patients with poor BP 
control. 
Logistic regression models 
 Unadjusted Adjusted to age-sex-systolic BP Fully adjusted*  N 
OR (95% CI) OR (95% CI) OR (95% CI) 
Age, yrs 6284 1.02 (1.011.02) 1.02 (1.011.02) 1.01 (1.011.02) 
Female 6284 1.04 (0.941.15) 1.06 (0.961.18) - 
Office measurements     
Systolic BP, per 10 mmHg 6284 1.07 (1.031.12) 1.06 (1.021.11) 1.06 (1.021.11) 
Diastolic BP, per 5 mmHg 6284 1.02 (0.991.05) 1.02 (0.991.05) - 
Pulse Pressure, per 10 mmHg 6284 1.05 (1.011.09) 0.98 (0.921.03) - 
Regular home BP measurement 6264 0.85 (0.760.94) 0.85 (0.770.95) 0.82 (0.740.92) 
Comorbidities and CV risk factors     
Coronary artery disease 6232 1.14 (1.021.27) 1.04 (0.931.17) - 
Heart failure 6220 1.11 (0.951.29) 0.97 (0.821.14) - 
Diabetes 6235 1.32 (1.171.48) 1.25 (1.111.41) 1.28 (1.131.44) 
Stroke or TIA 6239 1.03 (0.861.24) 0.94 (0.771.13) - 
Chronic kidney disease 5587 1.05 (0.861.28) 0.93 (0.751.14) - 
Current smoking 6263 0.86 (0.760.97) 0.88 (0.770.99) 0.87 (0.770.99) 
Abdominal obesity 6284 1.16 (1.041.28) 1.14 (1.031.27) 1.09 (0.981.21)╪ 
*Fully adjusted model included age; systolic BP; regular home BP measurement; diabetes; current smoking; abdominal obesity. ╪Removed 
due to backward elimination procedure in the stepwise logistic regression model. BP: blood pressure; CV: cardiovascular; TIA: transient 
ischemic attack. 
 
marizing the comparative analysis, we did not observe the 
effect of age in regards to the frequency of modification of 
the specific drug classes. However, in older patients signifi-
cantly fewer changes in combined therapy were observed. 
In summary, results of multivariate analysis demonstrated 
that higher office SBP wasn’t a predictor of therapy modi-
fication during the visit–—odds ratio (OR) and 95% confi-
dence limits (95% CL) was 0.99 (0.98–0.99). On contrary, 
the significant predictor for the therapy modification oc-
curred regular BP measurement at home (OR: 1.27, 1.13– 
1.44). Moreover, home measurements gained in importance 
in presence of co-morbidities such as diabetes (OR: 1.47, 
1.27–1.70), heart failure (OR: 1.34, 1.10–1.64) and chronic 
kidney disease (OR: 1.32, 1.03–1.70), and in males (OR: 
1.28, 1.13–1.44).  
3.5  Sensitivity analyses 
In general, physicians provided primary care (general 
practitioners, internal medicine specialists) represent 83.0 % 
of all surveyed physicians. Non-primary care physicians 
were 17.0% of the sample and they were represented by 
cardiologists (15.9%) and hypertension specialists (1.1%). 
We compared then the patients profile and hypertension 
management in relation to reference of medical care. De-
tailed data has been presented in the Supplemental material. 
In general, there was no significant difference in rela- 
Table 4.  Changes of hypertension therapy in the patients with poor hypertension control during the index visit according to the 
patients’ age category. 
 ≤ 64 yrs (n = 3895) 65–79 yrs (n = 2134) ≥ 80 yrs (n = 433) Ρ-value 
Any modification according to drug classes     
ACE inhibitor 1114 (28.6%) 753 (35.3%) 152 (35.1%) < 0.001 
ARB 316 (8.1%) 254 (11.9%) 36 (8.3%) 0.002 
β-blocker 1281 (32.9%) 1018 (47.7%) 211 (48.7%) < 0.001 
Calcium channel blocker 287 (7.4%) 227 (10.6%) 56 (12.9%) < 0.001 
Diuretic 529 (13.6%) 444 (20.8%) 113 (26.1%) < 0.001 
α-blocker or centrally acting 54 (1.4%) 71 (3.3%) 13 (3.0%) < 0.001 
Fixed-dose combination 440 (11.3%) 180 (8.4%) 37 (8.6%) 0.001 
Patients without any modification of HT therapy 1396 (35.8%) 520 (24.4%) 110 (25.4%) < 0.001 
Data are presented as n (%). ACE inhibitor: angiotensin-converting-enzyme inhibitor; ARB: angiotensin II receptor blocker; HT: hypertension. 
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tion to age of the patients, the prevalence of main CV risk 
factors (smoking, lipid disorders, central and abdominal 
obesity), systolic BP in the office, office PP and home BP 
level. The significance differences were observed in relation 
to gender distribution and co-morbidities—the prevalence 
of coronary heart disease, diabetes and chronic kidney dis-
eases was higher in patients non-primary care specialists 
(Supplemental Table S2). ACE inhibitors, calcium channel 
blockers, β-blockers and fixed-dose combination were sig-
nificantly often prescribed by non-primary than primary 
care specialists. Primary care specialists more frequently 
treated their patients with monotherapy or two drug classes, 
and made less modification in the treatment regimen (Sup-
plemental Table S3).  
4  Discussion 
The main finding of the study is that the large group 
(43%) of the studied patients with uncontrolled hyperten-
sion, especially from primary care settings were on a subop-
timal therapy. Although the older subjects were most likely 
to use three or more antihypertensive drug classes, a 
fixed-dose combinations were used only in one fifth of these 
patients. Furthermore, majority of the patients (61%) had 
their latest treatment modification more than six months 
from the study visit, and this concerned particularly older 
people with higher CV risk (co-existed higher office BP 
level and/or diabetes). The earlier modification of anti-
hypertensive therapy by the physician was associated with 
regular home BP monitoring by the patient. 
Suboptimal antihypertensive drug regimens remains sig-
nificant reason of poor BP control. In our study, only 51% 
of patients were on three or more antihypertensive drugs, 
including a diuretic, and these data correspond with results 
published earlier by Garg, et al.[12] Of 141 patients referred 
to a tertiary care clinic and who met the criteria for RHT, in 
58% the resistance was caused by suboptimal antihyperten-
sive therapy. By increasing the number of antihypertensive 
medications and/or optimizing the diuretic regimen, BP 
target was achieved in 53% of these patients.[12] Further-
more, among 468,877 hypertensive patients in a community- 
based practice network, 31.5% had uncontrolled hyperten-
sion. Of these, 30.3% (44,684) patients were receiving three 
or more medications, but only half of these patients were 
receiving optimal doses including a diuretic.[13] Independ-
ently of age, the most commonly used antihypertensive drug 
classes in our study were diuretics and ACE inhibitors, and 
these data correspond to the Pol-Fokus study.[14] Moreover, 
in our study and the Pol-Fokus data,[15] in older patients 
β-blockers were more frequently used than calcium channel 
blockers. In the very old (80 years and more) hypertensive 
population in the USA (NHANES 2005–2010), β-blockers 
were the most commonly prescribed, and then diuretics and 
ACE inhibitors.[16] The guidelines[11,17] suggest the first-line 
choice of antihypertensive drugs should take into account 
the co-existed chronic conditions. Although some data in-
dicating lack of sufficient evidence that different antihyper-
tensive regimens are superior in older (> 65 years) than 
younger (≤ 65 years) hypertensive patients in reducing CV 
events,[18] data from clinical trials[19–22] as well as expert 
recommendations[17] highlighted calcium channel blockers 
or thiazide-like diuretics as generally favourable for older 
people. 
The important discovery of our study seems to be a sub-
stantial range of clinical inertia among physicians. Spanish 
data indicated the physicians’ perception of BP control, 
being on treatment with combined therapy, and the absence 
of risk factors or CV disease as the main predictors of 
therapeutic inertia.[23] In our study, paradoxically the prob-
lem was particularly pronounced in relation to the patients 
with higher CV risk, which is in the older hypertensive pa-
tients with coexisted diabetes. Unfortunately, our data are 
complementary with previously published data from pri-
mary care settings in Poland, showing among primary care 
physicians poor compliance with hypertension treatment 
guidelines especially in diabetic patients.[24]  
We found that being older patient presenting higher sys-
tolic BP in the office was associated with less chance to 
earlier modification of antihypertensive treatment. It is 
known that poor BP control is generally more prevalent in 
oldest age,[15,25] and some clinical aspects should be consid-
ered in explanation of this association. The important factor 
potentially worsening BP control in the very old hyperten-
sive patients could be multimorbidity. Across Europe, the 
prevalence of multimorbidity is 31.4%, with the highest 
prevalence in Eastern and Central Europe.[26] In our study, 
the incidence of CV and non-CV comorbidities significantly 
increased with advanced age. Patients with poor BP control 
were more likely to have a concomitant medical condition 
than patients with optimal BP control.[27] Furthermore, 
mood or cognitive disturbances, even at a subclinical level, 
are also linked with poor control of BP and worse compli-
ance in older patients.[15] Besides, the clinical and pa-
tient-related reasons of poor BP control in older hyperten-
sive patients, one should also take into account the issue of 
therapeutic inertia among physicians. Our study has not 
been designed to point the potential causes of lack of modi-
fication or to evaluate changes in treatment during the index 
visit. We can only assume that the presence of several 
chronic diseases in older patients presenting symptoms of 
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frailty, makes decision on intensification of antihypertensive 
treatment more difficult, so as not to be iatrogenic at the 
same time.  
The still debatable issue is how far to lower BP values in 
older patients. The ESH/ESC guidelines recommend reduc-
ing SBP below 150/90 mmHg in older hypertensives in 
office settings.[11] The National Institute for Health and 
Clinical Excellence (NICE) hypertension guidelines [28] ad-
ditionally suggest in people ≥ 80 years old a daytime target 
for BP control of below 145/85 mmHg with ambulatory 
blood pressure monitoring. Taking into account the Euro-
pean recommendations of the patients involved to the our 
study, we found 10.8% patients over 80 years with good BP 
control. The well know SPRINT study suggest that more 
intensive treatment of hypertension and lowering systolic 
BP below 120 mmHg might be beneficial in reducing major 
CV events and death from any cause when compared to 
standard treatment.[29] However, this threshold seems to be 
too aggressive for example for frail older patients. 
Interesting data from a Swedish cross-sectional study 
examined the relationship between level of BP control and 
functional status, measured by speed of walking, and its 
influence on the risk of mortality in very old patients (85 
years and more).[30] The study indicated an increased risk of 
mortality with higher SBP and DBP (≥ 140/80 mmHg) but 
only in those with better functional condition, that is in the 
faster-walking subcohort (≥ 0.5 m/s). In very old non-walk-
ing or slowly walking people, lower BP (<140/80 mmHg) 
could in fact be a marker of increased risk of mortality. 
Thus, in line with current European recommendations, the 
decision about the therapeutic target in frail hypertensive 
octogenarians should be highly individualized and therefore 
finally left to the physician.[11] 
4.1  Strengths and limitations 
The strength of our study is a large sample of older out-
patients with uncontrolled BP have been characterized ac-
cording to antihypertensive treatment regimen as well as 
factors potentially modifiable the effectiveness of the ther-
apy. However, our older subjects were physically able to 
visit the physicians’ office so the study results cannot be 
extrapolated to whole group of older patients, in particular 
those with severe comorbidities or dementia, who are un-
able to leave home, as well as residents of a nursing homes.  
The cross-sectional design of the study based on the de-
clarative data obtained from the physicians is the most im-
portant study limitation. Because BP was gathered during a 
single visit, we cannot exclude that some of our patients 
presented the white-coat effect, in spite of recommended 
technique of BP measurement in office settings. Moreover, 
even if modifications of therapy were introduced during the 
previous visit, an improvement in hypertension control 
would not necessarily be achieved. Our study has an obser-
vational nature, therefore, in order to evaluate that issue 
more deeply and accurately, further research is needed.  
4.2  Conclusions 
Results of the presented study suggest that a large group 
of outpatients with uncontrolled BP receive suboptimal an-
tihypertensive therapy. In older patients, higher BP values 
seem to be more frequently accepted by physicians, who are 
less motivated to intensify therapy in spite of the higher 
cardiovascular risk in the patient. On the contrary, regular 
home BP monitoring positively affects the decision to mod-
ify antihypertensive treatment. 
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